Cargando…

Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease

Background: Parkinson’s disease is an aggressive and progressive neurodegenerative disorder that depletes dopamine (DA) in the central nervous system. Dopamine replacement therapy, mainly through actual dopamine and its original prodrug l-dopa (LD), faces many challenges such as poor blood brain bar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haddad, Fatma, Sawalha, Maryam, Khawaja, Yahya, Najjar, Anas, Karaman, Rafik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943940/ https://www.ncbi.nlm.nih.gov/pubmed/29295587 http://dx.doi.org/10.3390/molecules23010040

Ejemplares similares

Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years
por: Najjar, Anas, et al.
Publicado: (2020)

Advanced Prodrug Strategies in Nucleoside and Non-Nucleoside Antiviral Agents: A Review of the Recent Five Years
por: Sinokrot, Hanadi, et al.
Publicado: (2017)

Polymeric nanoparticles for dopamine and levodopa replacement in Parkinson's disease
por: Alabrahim, Obaydah Abd Alkader, et al.
Publicado: (2022)

Enzyme Models—From Catalysis to Prodrugs
por: Breijyeh, Zeinab, et al.
Publicado: (2021)

Antibacterial Prodrugs to Overcome Bacterial Resistance
por: Jubeh, Buthaina, et al.
Publicado: (2020)

Strategies for Enhancing the Permeation of CNS-Active Drugs through the Blood-Brain Barrier: A Review
por: Zeiadeh, Isra’, et al.
Publicado: (2018)

Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist
por: Zhang, Jinglin, et al.
Publicado: (2016)

Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease
por: Picillo, Marina, et al.
Publicado: (2020)

Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
por: Bargiotas, Panagiotis, et al.
Publicado: (2013)

A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19
por: Haddad, Fatma, et al.
Publicado: (2022)

Dopamine pathway and Parkinson's risk variants are associated with levodopa-induced dyskinesia
por: Sosero, Yuri L., et al.
Publicado: (2023)

A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
por: Haddad, Fatma, et al.
Publicado: (2023)

Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease
por: Palacios, Natalia, et al.
Publicado: (2021)

Mechanisms of peripheral levodopa resistance in Parkinson’s disease
por: Beckers, Milan, et al.
Publicado: (2022)

Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease
por: Poulopoulos, Markos, et al.
Publicado: (2010)

Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
por: Poewe, Werner, et al.
Publicado: (2010)

Evaluating Opicapone as Add-on Treatment to Levodopa/DDCI in Patients with Parkinson’s Disease
por: Jost, Wolfgang H
Publicado: (2022)

Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies
por: Kwon, Destany K., et al.
Publicado: (2022)

The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms
por: Haddad, Fatma, et al.
Publicado: (2022)

Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
por: Conti, Valeria, et al.
Publicado: (2022)

Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson's Disease
por: Guridi, J., et al.
Publicado: (2012)

Dopamine Transporter Density in de novo Parkinson’s Disease Does Not Relate to the Development of Levodopa-Induced Dyskinesias
por: Roussakis, Andreas-Antonios, et al.
Publicado: (2019)

Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
por: Krishnan, Syam, et al.
Publicado: (2017)

Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference
por: Müller, Thomas
Publicado: (2009)

Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date
por: Patel, Ami B, et al.
Publicado: (2018)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
por: Antonini, Angelo
Publicado: (2009)

Continuous levodopa for advanced Parkinson’s disease
por: Lundqvist, Christofer
Publicado: (2007)

Mortality in Levodopa-Treated Parkinson's Disease
por: Morgan, John C., et al.
Publicado: (2014)

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease
por: Margolesky, Jason, et al.
Publicado: (2017)

A Comprehensive Review on the Anti-Cancer Effects of Oleuropein
por: Rishmawi, Sabreen, et al.
Publicado: (2022)

Biodegradable Nanoparticles Loaded with Levodopa and Curcumin for Treatment of Parkinson’s Disease
por: Mogharbel, Bassam Felipe, et al.
Publicado: (2022)

Embelin and levodopa combination therapy for improved Parkinson’s disease treatment
por: Ramachandra, Vagdevi Hangarakatte, et al.
Publicado: (2022)

Effects of Oral Levodopa on Balance in People with Idiopathic Parkinson’s Disease
por: Leroy, Tim, et al.
Publicado: (2023)

Modulation of Habit Formation by Levodopa in Parkinson's Disease
por: Marzinzik, Frank, et al.
Publicado: (2011)

“Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Schaeffer, Eva, et al.
Publicado: (2016)

Development of new levodopa treatment strategies in Parkinson’s disease—from bedside to bench to bedside
por: Aquilonius, Sten-Magnus, et al.
Publicado: (2017)

Design, Synthesis, and In Vitro Kinetics Study of Atenolol Prodrugs for the Use in Aqueous Formulations
por: Karaman, Rafik, et al.
Publicado: (2014)

Combined and Sequential Treatment with Deep Brain Stimulation and Continuous Intrajejunal Levodopa Infusion for Parkinson’s Disease
por: van Poppelen, Daniël, et al.
Publicado: (2021)

Levodopa-Carbidopa Intestinal Gel may improve treatment-resistant freezing of gait in Parkinson’s disease
por: Shackleford, Melanie R., et al.
Publicado: (2022)

Comparison of Endothelial Progenitor Cells in Parkinson's Disease Patients Treated with Levodopa and Levodopa/COMT Inhibitor
por: Lee, Phil Hyu, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_jm0p17mth95b3gb6l400u0obm8